Search PubMed⌕ Search

Biomedical subjects

M Fromer

Publications and source records attributed to M Fromer.

At least 19 recordsLinked to original sources
PubMed1995

[Permanent junctional reciprocating tachycardia: a little-known clinical entity curable with radiofrequency ablation].

We report our experience of 5 patients with the permanent form of junctional reciprocating tachycardia (PJRT), a rare form of supraventricular arrhythmia. PJRT was discovered at a mean age of 31 years (8-60 years) and the mean duration of tachycardia was 13 years (1-40 years). 4 patients had nearly incessant tachycardia and one had paroxysmal attacks. Heart rate varied between 100 and 190 beats/minute and the minimal heart rate was on average 114 beats/minute. Four patients had palpitations, 2 developed tachycardia-induced cardiomyopathy, reversible after control of the arrhythmia, and 4 had asymptomatic episodes of PJRT. ECG showed in all cases a narrow-complex tachycardia with inverted P waves in inferior leads and RP interval greater than PR. All patients presented a posteroseptal accessory pathway. 4 patients received different antiarrhythmic drugs with only partially effective results. Radiofrequency catheter ablation of the accessory pathway was performed in all patients and was successful in 4, who remained free of recurrence after a mean follow-up of 26.5 months (4-37 months). The procedure was partially successful in the 5th patient, who is now asymptomatic under sotalol. Radiofrequency catheter ablation is therefore the treatment of choice of PJRT, a rare arrhythmia which should nevertheless be known in order to treat the patient correctly and avoid progression to cardiac failure, which is not always completely reversible.

Adolescent↗
PubMed1994

[Endocavitary percutaneous ablation of tachyarrhythmias].

The indication and result of catheter ablation for supraventricular and ventricular arrhythmias are reviewed, with special emphasis on the need to inform the patient undergoing this type of procedure, the possible complications and our center's results.

Atrial Flutter↗
PubMed1994

[Mortality following sustained ventricular tachycardia treated according to the results of programmed ventricular stimulation].

The purpose of this study was to evaluate longterm mortality in 44 patients undergoing electrophysiologically guided therapy for sustained monomorphic ventricular tachycardia. We applied the following modified response criteria: non-inducibility or slowing of induced ventricular tachycardia to < or = 150 bpm. On this basis, 25/44 (57%) patients were classified as responders, and 19/44 (43%) as non-responders. Responders had palpitations significantly more often as the leading clinical sign (68% vs. 21%, p < 0.05). Non-responders showed a lower mean ejection fraction (36 +/- 15% vs. 46 +/- 17%, p < 0.05) and a trend to higher incidence of syncopal ventricular tachycardia (58% vs. 12%, p = 0.15). All responders and 3/19 non-responders continued on drug therapy. 11 non-responders received an implantable cardioverter-defibrillator (ICD), 3 underwent surgery and 2 catheter ablation. 14/44 patients (32%) died during a mean follow-up of 3.2 years. Sudden arrhythmic death occurred in 3/28 patients on drug therapy (1/25 responders, 2/3 non-responders), and in 2/16 non-responders with invasive therapy (one with an ICD and one after catheter ablation). The cumulative all-cause mortality at 3 years was similar in both groups (26% vs 22%, n.s.), but the mortality from sudden arrhythmic death showed a trend to be lower in the responder-group (0% vs 17%, p = 0.09).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1994

Relation between cycle length, volume, and pressure in type I atrial flutter.

Assuming that type I atrial flutter is a macroreentrant circuit, its cycle length should vary with the atrial dimensions. In order to test this hypothesis, flutter cycle length was measured while inducing atrial volume and pressure changes by postural and pharmacological means in seven patients undergoing a therapeutic programmed stimulation for type I atrial flutter conversion. Right atrial volume was estimated from B-mode echocardiography data. Basal values were compared with those obtained during inspiration, expiration, Valsalva maneuver, negative tilt (head down), and positive tilt (head up) with 0.8-1.6 mg p.o. nitroglycerin. The right atrial size increased slightly from 17.8 to 18.3 cm2 (P = 0.04) during the pressure load induced by negative tilt (+3 mmHg), with a corresponding lengthening of the flutter cycle length from 228 to 233 msec (P = 0.02). Similarly, pressure unloading of -2 mmHg by positive tilting and nitrates was accompanied by a decrease in right atrial size to 16.6 cm2 (P = 0.04), with a corresponding decrease in cycle length from 228 to 219 msec (P = 0.03). Respiratory maneuver yielded similar results with an inspiratory cycle lengthening, expiratory shortening, and further shortening during Valsalva maneuver. These experiments demonstrate a direct relation between cycle length and atrial volume in human type I atrial flutter. They underline the importance of the right heart preload and atrial size for the electrophysiological characteristics of type I atrial flutter. Beside its fundamental interest, this finding is important for the understanding of the mechanism of maintenance and therapeutic responses of this common arrhythmia.

Atrial Flutter↗
PubMed1994

Autonomic imbalance assessed by heart rate variability analysis in vasovagal syncope.

In this prospective study, the autonomic modulation of the sinus node of 12 patients (mean age 28 +/- 7 years) suffering from vasovagal syncope (VVS) was compared to that of 11 sex and age matched control patients (mean age 32 +/- 4 years) by analysis of heart rate variability. Spectral indices (low frequency power [Plf], high frequency power [Phf], total power [Pt], sympathovagal balance [LF/HF]) and temporal indices, the mean of all coupling intervals between normal beats (mRR), the standard deviation about the mean (sdRR), the percentage of adjacent R to R intervals differing by more than 50 msec (pNN50), and the root mean square of variations in successive R to R intervals (rMSSD) were compared at baseline and during head-up tilt between and within groups. Baseline results were similar in both groups. During tilt testing, comparison of results between groups revealed only significantly higher sdRR and rMSSD and lower LF/HF ratio in VVS patients. Within VVS patients, comparison of temporal and spectral analysis between baseline and tilt showed a significant increase of most indices (Plf, Phf, Pt, sdRR, and rMSSD) but a comparable LF/HF ratio; in contrast, control patients exhibited only a significant increase of LF/HF ratio. In conclusion, VVS patients who developed vasovagal syncope during head-up tilt demonstrated a nonreciprocal modulation of the sinus node by the autonomic nervous system indicative of a pronounced physiological sympathetic surge along with a paradoxical vagal input to the cardiovascular system.

Adult↗
PubMed1994

[Primary ventricular fibrillation and early recurrence: apropos of a case of association of right bundle branch block and persistent ST segment elevation].

The authors report the case of a 36 year old man who presented with an early recurrence of primary ventricular fibrillation. The initial investigations were normal apart from the finding of complete right bundle branch block with persistent ST segment elevation in the right precordial leads. The recurrence was observed 6 weeks after the initial diagnosis which led to the implantation of an automatic defibrillator. This clinical case is similar to a syndrome recently described of sudden death without obvious cardiac disease but with right bundle branch block and ST segment elevation.

Adult↗
PubMed1993

Acute and long-term ventricular stimulation thresholds with a new, iridium oxide-coated electrode.

Efforts have been made to design electrodes that significantly reduce not only the acute and chronic stimulation thresholds, but also attenuate the early peaking phenomenon and polarization. At two voltage levels (2.7 V and 5.4 V, respectively), we evaluated the right ventricular stimulation thresholds obtained with a new, iridium oxide-coated electrode in ten patients who received a VVI pacemaker. Measurements were made at implant and at multiple intervals for 1 year. Pulse width stimulation thresholds at implant were as follow: 0.04 +/- 0.008 msec at 2.7 V, 0.03 +/- 0.004 msec at 5.4 V; values at 2 weeks were 0.14 +/- 0.06 msec at 2.7 V, 0.07 +/- 0.025 msec at 5.4 V; values at 3 months were 0.09 +/- 0.03 msec at 2.7 V, 0.05 +/- 0.01 msec at 5.4 V; values at 1 year were 0.08 +/- 0.02 msec at 2.7 V, 0.04 +/- 0.01 msec at 5.4 V. The maximal increase of 0.11 +/- 0.05 msec occurred at 2.7 V, 2 weeks after implant. Our results indicate that this new electrode provides low acute and long-term stimulation thresholds, as well as an attenuated early peaking phenomenon, being able to stimulate safely at 2.7 V even early after implant.

Aged↗
PubMed1993

[Initial experience of percutaneous catheter ablation using radiofrequency of atrioventricular accessory pathways].

This paper reports the authors' preliminary experience in catheter ablation by radiofrequency current of 46 accessory atrioventricular pathways in 45 symptomatic patients with supraventricular tachyarrhythmias resistant to medical therapy. With an average follow-up period of 5.5 +/- 4 months the global success rate was 80%, ranging from 96% in left lateral to 33% in antero septal accessory pathways. It increased from 65% in the first 20 patients to 88% in the last 25 patients. The average duration of radioscopy was significantly shorter in left lateral pathways than in other localisations (p < 0.02); it was also shorter when ablation was successful. Complications were observed in 4 patients (9%) and included one complete atrioventricular block and 3 femoral arterial lesions. Anaesthetic assistance was required in 14 cases (31%), either at the patient's request or to allow reduction of atrial fibrillation. Percutaneous catheter ablation of accessory atrioventricular pathways with radiofrequency current is effective and gives good results; very strict selection of initial patients and the respect of certain conditions taking into account the experience of the medical team, the technically difficult approach of certain accessory pathways and the risks of ablation of pathways running near the atrioventricular node or His bundle, are necessary for successful results when learning this technique.

Adolescent↗
PubMed1992

[Endocavitary ablation: a new therapeutic approach to supraventricular tachycardia].

Nowadays patients suffering from supraventricular tachycardia are first treated with antiarrhythmic drugs. In refractory cases alternative treatment is antitachycardia pacemaker implantation or surgery. Recently new percutaneous catheter techniques have been developed to ablate directly the anatomical substrate responsible for the arrhythmia by delivering energy (high or low energy shock or radiofrequency) at the tip of a catheter. This article summarizes the results of clinical application of these different techniques and briefly presents our experience. The very recent studies with RF in patients with drug-refractory av nodal reentry or accessory pathway related tachycardia (WPW syndrome) report a success rate of 92-99% with a very low complication rate. If the long term success of radiofrequency is confirmed this technique will emerge in the near future as the treatment of choice in patients suffering from symptomatic supraventricular tachycardia, since it avoids expensive, longlasting drug treatment with the permanent risk of side effects.

Atrial Fibrillation↗
PubMed1992

[Circadian variability of rhythm disorders].

Cardiac arrhythmias exhibit also a circadian variability. It is impressingly apparent in sustained ventricular tachycardia and sudden cardiac death. Adrenergic stimulation during morning hours, a physiologic event for the transition from nocturnal to diurnal activity, appears to be an important arrhythmogenic factor (25). The results of the BHAT-study show that beta blocking agents may substantially reduce the risk for sudden cardiac death during morning hours. This notion should thus be considered in treating patients at risk.

Arrhythmias, Cardiac↗
PubMed1992

Ultrarapid subthreshold stimulation for termination of atrioventricular node reentrant tachycardia.

OBJECTIVES: We investigated the efficacy and safety of ultrarapid subthreshold electrical stimuli in terminating sustained atrioventricular (AV) node reentrant tachycardia. BACKGROUND: Subthreshold stimuli, singly and in trains, have been reported to prolong the effective refractory period, inhibit the response to subsequent suprathreshold extrastimuli and to terminate ventricular tachycardia and reciprocating tachycardia. METHODS: Seventeen consecutive patients with inducible sustained slow-fast AV node reentrant tachycardia (mean tachycardia cycle length 358 +/- 61 ms) were studied. Trains of subthreshold stimuli were tested at various right atrial sites. RESULTS: Trains of subthreshold stimuli reproducibly terminated AV node reentrant tachycardia in 15 patients without administration of adjunctive pharmacologic agents. Effective subthreshold current strength ranged from 0.5 to 1.5 mA (mean 0.9 +/- 0.3). The cycle length of effective subthreshold stimuli trains ranged from 30 to 80 ms (mean 57 +/- 17), and the number of stimuli in the train ranged from 4 to 16 (mean 8 +/- 4). The site of successful termination was the proximal coronary sinus in 6 patients and the right low atrial septum in 12. During successful subthreshold termination, no atrial capture could be detected. Neither atrial fibrillation nor flutter nor tachycardia acceleration occurred. CONCLUSIONS: Low current, high frequency trains of stimuli, when applied at a site presumed to be close to the reentrant circuit, provided a safe and effective method of terminating the common type of AV node reentrant tachycardia. This technique could be used to identify critical parts of the reentrant circuit suitable for ablation and further investigations with this method are warranted.

Adult↗
PubMed1992

Subthreshold electrical stimulation for termination and prevention of reentrant tachycardias.

Subthreshold electrical stimulation (STS) was used to terminate and prevent reentrant supraventricular and ventricular (VT) tachycardia. Of 12 patients with SVT, 8 had atrioventricular nodal (AVN) reentry, and 4 had orthodromic tachycardias. Trains of STS applied close to the AVN area terminated the tachycardias in five of the eight patients with AVN re-entry and two of the patients with orthodromic tachycardia. In 13 patients with recurrent sustained hemodynamically stable VT (mean cycle length 370 +/- 40 ms), trains of STS were delivered at the site of early activity during the tachycardia. Number of train cycles ranged between 3 to 8 pulses and their cycle lengths ranged between 20 and 70 ms. In 7 of the 13 patients VTs were effectively terminated by STS application close to the site of early activity and in the remaining 6 patients it did not. In nine patients the effect of STS applied at the site of early activity on VT induction from the right ventricular apex was examined. In four of the nine patients STS prevented VT induction and in the remaining five patients it did not. These observations suggest that STS applied in proximity to the area critical for initiation and maintenance of reentry can terminate or prevent induction of the tachycardia.

Adult↗
PubMed1992

Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.

BACKGROUND: Third-generation implantable cardioverter-defibrillators are devices designed to treat ventricular tachycardia (VT) and ventricular fibrillation (VF) by means of overdrive pacing, cardioversion, or defibrillation. So far, the efficacy of tiered therapy has been documented only in small series. Therefore, a European multicenter clinical evaluation study of a new tachyarrhythmia control device, the Medtronic PCD pacer-cardioverter-defibrillator with epicardial patch-lead configuration, was undertaken. METHODS AND RESULTS: We report on 102 patients (mean age, 55 +/- 13 years) from 11 European centers. PCD devices implanted between May 1989 and February 1991 were included. The patients suffered from hemodynamically significant ventricular tachyarrhythmias not suppressed by antiarrhythmic drug therapy and unrelated to acute myocardial infarction; one patient had nonsustained VT and severely depressed left ventricular function. Seventy patients had coronary artery disease with old myocardial infarctions, 23 had cardiomyopathies of various etiologies, and nine patients had no detectable heart disease. Mean ejection fraction was 36 +/- 14% (range, 10-76%). Mean intraoperative defibrillation threshold (51 patients) was 10.6 +/- 5.1 J (range, 2-18 J). The documented follow-up ranged from 1 to 21 months (mean, 9.4 +/- 5.8 months), or 79.9 cumulative patient-years. Perioperative mortality was 3.9%. The actuarial survival rate at 12 months was 91%. One sudden arrhythmic death occurred. Sixty patients (58%) received device therapy. Seventeen patients had therapies only for "VF" episodes, 16 patients only for VT, and 28 patients for VT and "VF" episodes. Based on device memory data, 1,235 spontaneous VT episodes were detected and treated in 43 patients. Twelve hundred four of these VT episodes received painless initial antitachycardia pacing therapy, restoring sinus rhythm in 91%. The 108 ongoing episodes received 209 multiple therapeutic attempts. Eighty-five additional overdrive pacing therapies restored sinus rhythm in 30%. Initial ineffective antitachycardia pacing therapies received 51 cardioversion pulses. The success rate was 61%. Seventy-three additional cardioversion pulses were delivered to backup ineffective pacing therapy as well as ineffective secondary cardioversion pulses. Their success rate was only 40%. Two hundred eighty-six spontaneous episodes were detected in 44 patients as "VF." Overall defibrillation efficacy was 97.6%. CONCLUSIONS: The implanted device nearly eliminates sudden arrhythmic death in patients with documented, potentially fatal ventricular tachyarrhythmias. Automatic tiered therapy is highly effective to restore sinus rhythm, provided that an integrated two-zone tachycardia detection algorithm is used, assigning lower tachycardia rates to overdrive pacing and/or cardioversion and higher tachycardia rates to defibrillation. In general, spontaneous VTs can be terminated by automatic overdrive pacing, and painful or disturbing countershock therapies are not required to terminate the majority of spontaneous VT episodes.

Death, Sudden, Cardiac↗
PubMed1992

[Sudden cardiac death: possibilities of interventional therapy].

There is, at present, no method to prevent sudden cardiac death. However, in patients with documented high risk the implantable automatic cardioverter defibrillator is the only reliable alternative. However, the electrical discharges of high energy may cause discomfort and pain. Antitachycardia pacing is effective for most episodes of ventricular tachycardia and can effectively reduce the number of electrical shocks to be delivered.

Death, Sudden, Cardiac↗
PubMed1992

Transcatheter ablation of cardiac tissue: advantages and disadvantages of different ablative techniques.

Transcatheter ablation techniques are emerging as an alternative therapeutical tool in the management of cardiac arrhythmias. Catheter ablation was initially introduced as the last resort to ablate the atrioventricular nodal conduction in patients with atrial fibrillation and uncontrolled ventricular response and in patients with drug refractory ventricular tachycardias. Direct current energy was used as the sole source of energy, but because of potential significant complications and early and late mortality, presumably mostly due to ventricular tachyarrhythmias, other sources of energy were sought. Radiofrequency current which does not produce barotrauma and does not require general anesthesia rapidly replaced direct current ablation in many centers. Early results with radiofrequency current ablation of the atrioventricular node and accessory atrioventricular pathways are very encouraging. The results of radiofrequency as well as direct current ablation for atrial flutter, atrial tachycardia and ventricular tachycardia, where the components of reentry circuit are less defined, are not as favorable as those of AV junctional tachycardias. However, improvement of catheter and generatory technology and better understanding of the mechanisms of ventricular tachycardias and characteristics of the target site will enhance the results of catheter ablation in ventricular tachcardias. The procedures are still considered investigational, and mostly done by very experienced groups at tertiary referral hospitals with surgical teams available in case of serious complications. Larger patient populations and longer follow-up periods are required before these techniques expand to community hospitals and to patients with minimal symptoms or asymptomatic individuals as a prophylaxis therapy.

Cardiac Catheterization↗
PubMed1991

Experience with a new implantable pacer-, cardioverter-defibrillator for the therapy of recurrent sustained ventricular tachyarrhythmias: a step toward a universal ventricular tachyarrhythmia control device.

Ten consecutive patients (mean age 57.9 +/- 7.6 years) were treated with an investigational tachyarrhythmia control device, the implantable Medtronic Pacer-, Cardioverter-, Defibrillator model 7216A or 7217B. All patients had coronary artery disease with old myocardial infarctions and presented hemodynamically significant sustained ventricular tachyarrhythmias not suppressed by antiarrhythmic drug therapy and unrelated to acute myocardial infarction. In two patients a nonthoracotomy lead system was implanted. Lowest effective defibrillation energy ranged from 5 to 18 joules (mean 12.2 +/- 4 joules) for the epicardial bielectrode systems and were 15 and 18 joules for the nonthoracotomy lead system implants. The postoperative periods were unremarkable. Follow-up ranged from 7 to 19 months (mean 13.8 +/- 4.5 months). Spontaneous tachyarrhythmia episodes were detected and treated by the device in six patients, five of them received staged therapies. No deaths occurred and no hospital admissions were necessary for device related or ventricular tachyarrhythmia related complications. In conclusion, this integrated device represents a major step toward the development of a universal ventricular arrhythmia control device.

Aged↗
PubMed1991

Antiarrhythmic treatment of atrioventricular tachycardias.

Atrioventricular (AV) tachycardia includes both AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT) using an accessory pathway. The treatment of the acute attack is different from the long-term treatment of both AVNRT and AVRT. Verapamil and adenosine, by prolonging the refractory period of the AV node, are highly effective in terminating acute attacks of AVNRT and orthodromic AVRT. Conversion to sinus rhythm is achieved in approximately 90% of the episodes of tachycardias with both agents given intravenously. The initial dose of verapamil is 0.075-0.1 mg/kg and a subsequent bolus of 5 mg can be given to a maximal dose of 15-20 mg. The initial dose of adenosine is 3 or 6 mg, but doses of 9 or 12 mg can be administered if smaller dosages have been unsuccessful. Other agents producing lengthening of the refractory period of the accessory pathway in AVRT or of the fast pathway in AVNRT often terminate reentry tachycardia. Such agents are class IC antiarrhythmic drugs such as flecainide or propafenone and class IA drugs such as procainamide. In patients with accessory pathways and antidromic tachycardia or atrial fibrillation conducting via an accessory pathway, treatment with verapamil or digoxin should be avoided because these agents may enhance the conduction properties of the accessory pathway, thereby leading to an increase of the ventricular rate or even to ventricular fibrillation. Prevention of AVNRT episodes can be obtained with various antiarrhythmic drugs. Digoxin alone or in combination with beta-blockers is effective in approximately 50% of the cases and especially when the combination proved to be successful during electrophysiological testing.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗